Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
Marker Therapeutics news
13.05.2022
Marker Therapeutics' GAAP loss for 3 months of 2022 was $9.91 million, up 12.9% from $8.779 million in the prior year. Revenue was $964,322,000. The company did not generate revenue a year earlier.
Source: 
ir.markertherapeutics.com
ir.markertherapeutics.com
18.03.2022
Marker Therapeutics' GAAP loss for 2021 was $41.879 million, up 45.9% from $28.706 million in the prior year. Revenue increased 2.7 times to $1.242 million from $0.466 million a year earlier.
Source: ir.markertherapeutics.com
ir.markertherapeutics.com
20.01.2022
FDA has granted orphan drug status to MT-601, which is being developed by Marker Therapeutics. The drug is intended to treat people with pancreatic cancer and contains multiple tumor antigens. Drugs with this status can receive grants from the FDA to cover the costs of clinical trials, tax credits and seven years of market exclusivity in the U.S. after appro...
Source: ir.markertherapeutics.com
ir.markertherapeutics.com
11.11.2021
Marker Therapeutics' GAAP loss for 9M 2021 was $32.116 million, up 59% from $20.199 million in the prior year. The company did not generate revenue. A year earlier, the figure was $466,785 thousand.
Source: ir.markertherapeutics.com
ir.markertherapeutics.com
General information
| Company name | Marker Therapeutics |
|---|---|
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
| Business address | 3200 SOUTHWEST FREEWAY SUITE 2240 HOUSTON TX 77027 (713) 400-6400 |
| Mailing address | 3200 SOUTHWEST FREEWAY SUITE 2240 HOUSTON TX 77027 |
| Website | www.markertherapeutics.com |
| Information disclosure | www.sec.gov |
English (US) 